You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
BioSkryb will now have an exclusive global license for clinical applications of primary template directed amplification technology.
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.
The company believes results from a new study help demonstrate the clinical value of its targeted RNA-seq method, an add-on to its DNA hereditary cancer tests.
Kindstar has also agreed to purchase Genesis systems for use by its scientists to monitor circulating tumor cells and for single-cell research.
